Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 40,000 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 40,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the sale, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. The trade was a 96.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $105.29, for a total value of $193,733.60.
• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $120.00, for a total value of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $101.95, for a total value of $264,458.30.

Mirum Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ:MIRM traded up $1.37 on Wednesday, hitting $102.24. 556,260 shares of the company’s stock were exchanged, compared to its average volume of 885,061. Mirum Pharmaceuticals, Inc. has a 12 month low of $63.23 and a 12 month high of $130.00. The stock has a market capitalization of $6.64 billion, a price-to-earnings ratio of -7.03 and a beta of 0.52. The business’s 50 day simple moving average is $111.14 and its two-hundred day simple moving average is $102.03. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The company had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.12) earnings per share. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Royal Bank Of Canada decreased their price objective on Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Finally, Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $137.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Mirum Pharmaceuticals by 3.1% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 68,725 shares of the company’s stock valued at $8,046,000 after acquiring an additional 2,096 shares during the period. Toth Financial Advisory Corp purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth $1,204,000. Hsbc Holdings PLC bought a new stake in Mirum Pharmaceuticals during the second quarter valued at about $1,457,000. Empowered Funds LLC purchased a new position in Mirum Pharmaceuticals in the second quarter valued at about $229,000. Finally, Jefferies Financial Group Inc. bought a new position in Mirum Pharmaceuticals in the second quarter worth about $4,596,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.